| abstract |
The invention relates to novel compounds of formula (I) wherein n is an integer inclusive of 1 to 3; m is a whole included inclusively between 0 and 6; Ra represents a hydroxy group, a C1-C6 alkoxy group C6, aryloxy or arylalkyloxy; R1 and R2 independently represent a hydrogen atom or halogen, or an alkyl, C 1 -C 6 alkoxy, hydroxy or perhaloalkyl C1-C6 alkyl; R3 represents a hydrogen atom or an alkyl, arylalkyl group, cycloalkylalkyl, aryl or cycloalkyl; T1 represents an alkylene group, O-alkylene, alkylene-O- or alkylene-O-alkylene in which the alkylene groups behave each 1 to 3 carbon atoms; and G represents a group G1- or G1-T2-A-, in which A represents an aryl group, T2 represents a bond or a group alkylene, O-alkylene, alkylene-O- or alkylene-O-alkylene in which the groups alkylene each have 1 to 3 carbon atoms, G 1 represents a group -NR4R5, wherein R4 and R5 independently represent a hydrogen atom or one alkyl, cycloalkyl, aryl, arylalkyl, cycloalkylalkyl, heteroaryl or optionally substituted heteroarylalkyl, or else G1 represents a group heterocycloalkyl of formula having 5 to 7 members, wherein Y represent a nitrogen or oxygen atom, or a group CH or CH2 and R6 represents a atom hydrogen or an alkyl, cycloalkyl, cycloalkylalkyl or aryl group, arylalkyl, arylcarbonyl, arylcarbonylalkyl, diarylalkyl, diarylalkenyl, (Aryl) (hydroxy) alkyl, heteroaryl, heteroarylalkyl, heteroarylcarbonyl, or hétéroarylcarbonylalkyle. The invention also relates to the enantiomers and diastereoisomers of the compounds Formula (I), and their addition salts with an acid or a base pharmaceutically acceptable. The compounds according to the invention are useful for the manufacture of medicaments destined for to be used as TXA2 receptor antagonists and HT2, or used in the treatment of atherosclerotic cardiovascular thrombotic asthma, pinprasas, migraine or venous diseases. |